Analysts Issue Forecasts for CATX Q4 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Equities researchers at HC Wainwright issued their Q4 2024 earnings per share estimates for shares of Perspective Therapeutics in a research note issued to investors on Thursday, March 13th. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($0.24) for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics’ Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.19) EPS.

Other analysts also recently issued reports about the company. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Scotiabank initiated coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $14.56.

Perspective Therapeutics Price Performance

NYSE:CATX opened at $2.59 on Friday. The business’s 50-day moving average is $3.14 and its two-hundred day moving average is $7.32. Perspective Therapeutics has a 12 month low of $2.32 and a 12 month high of $19.05.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CATX. Y Intercept Hong Kong Ltd acquired a new position in Perspective Therapeutics in the fourth quarter valued at approximately $33,000. Aigen Investment Management LP acquired a new position in Perspective Therapeutics in the fourth quarter valued at approximately $34,000. National Bank of Canada FI boosted its stake in Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after acquiring an additional 10,998 shares during the period. ProShare Advisors LLC boosted its stake in Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after acquiring an additional 5,011 shares during the period. Finally, Vontobel Holding Ltd. acquired a new position in Perspective Therapeutics in the fourth quarter valued at approximately $51,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.